Search

Your search keyword '"Goncharova I"' showing total 9 results
Start Over Author "Goncharova I" Database OAIster
9 results on '"Goncharova I"'

1. Neogene Regional Scale of the Eastern Paratethys, Stratigraphy and Paleontological Basis

Author

Popov, S. V., Golovina, L. A., Palcu, D. V., Goncharova, I. A., Pinchuk, T. N., Rostovtseva, Yu V., Akhmetiev, M. A., Aleksandrova, G. N., Zaporozhets, N. I., Bannikov, A. F., Bylinskaya, M. E., Lazarev, S. Yu, Popov, S. V., Golovina, L. A., Palcu, D. V., Goncharova, I. A., Pinchuk, T. N., Rostovtseva, Yu V., Akhmetiev, M. A., Aleksandrova, G. N., Zaporozhets, N. I., Bannikov, A. F., Bylinskaya, M. E., and Lazarev, S. Yu

Abstract

Abstract: The stratigraphic scale of the Eastern Paratethys is revised based on a study of the Neogene stratotype and reference sections, their biotic characteristics, and paleomagnetic and sedimentological data. New data on the correlation of its regional subdivisions with the Central Paratethys and Mediterranean stratotypes are presented. The section “Regional Stage Scale of the Eastern Paratethys” considers the history of identification and a brief description of the horizons of the regional scale, which later became regional stages, as well as their historical stratotypes and lectostratotypes, and division into Beds and Substages. The section “History of Separate Biota Groups” provides reviews on the most important groups of fauna, phytoplankton, and terrestrial vegetation, as well as on magnetostratigraphy, the possibility of correlation and dating of sections based on these data, and comparison with the Central Paratethys and stratotypes of the Mediterranean. In conclusion, the main results of the revision of the stratigraphic scheme of the Neogene of the Eastern Paratethys are given.

Published
2022

2. Neogene Regional Scale of the Eastern Paratethys, Stratigraphy and Paleontological Basis

Author

Paleomagnetism, Popov, S. V., Golovina, L. A., Palcu, D. V., Goncharova, I. A., Pinchuk, T. N., Rostovtseva, Yu V., Akhmetiev, M. A., Aleksandrova, G. N., Zaporozhets, N. I., Bannikov, A. F., Bylinskaya, M. E., Lazarev, S. Yu, Paleomagnetism, Popov, S. V., Golovina, L. A., Palcu, D. V., Goncharova, I. A., Pinchuk, T. N., Rostovtseva, Yu V., Akhmetiev, M. A., Aleksandrova, G. N., Zaporozhets, N. I., Bannikov, A. F., Bylinskaya, M. E., and Lazarev, S. Yu

Published
2022

3. Neogene Regional Scale of the Eastern Paratethys, Stratigraphy and Paleontological Basis

Author

Paleomagnetism, Popov, S. V., Golovina, L. A., Palcu, D. V., Goncharova, I. A., Pinchuk, T. N., Rostovtseva, Yu V., Akhmetiev, M. A., Aleksandrova, G. N., Zaporozhets, N. I., Bannikov, A. F., Bylinskaya, M. E., Lazarev, S. Yu, Paleomagnetism, Popov, S. V., Golovina, L. A., Palcu, D. V., Goncharova, I. A., Pinchuk, T. N., Rostovtseva, Yu V., Akhmetiev, M. A., Aleksandrova, G. N., Zaporozhets, N. I., Bannikov, A. F., Bylinskaya, M. E., and Lazarev, S. Yu

Published
2022

5. Diagnosis of Impairments in the Hemostatic System in the Use of Warfarin in Cardiac Surgical Patients

Author

E. Goncharova I.; A. A. Vishnevsky Central Military Clinical Hospital Three, Ministry of Defense of the Russian Federation, E. Spiridonova A.; Dmitry Rogachev Federal ResearchandClinical Center for Pediatric Hematology, Oncology, and Immunology, Ministry of Health of the Russian Federation; A. I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the Russian Federation, A. Balandina N.; Dmitry Rogachev Federal ResearchandClinical Center for Pediatric Hematology, Oncology, and Immunology, Ministry of Health of the Russian Federation, A. Poletaev V.; Dmitry Rogachev Federal ResearchandClinical Center for Pediatric Hematology, Oncology, and Immunology, Ministry of Health of the Russian Federation, A. Sepoyan M.; Dmitry Rogachev Federal ResearchandClinical Center for Pediatric Hematology, Oncology, and Immunology, Ministry of Health of the Russian Federation, F. Ataullakhanov I.; Dmitry Rogachev Federal ResearchandClinical Center for Pediatric Hematology, Oncology, and Immunology, Ministry of Health of the Russian Federation; Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, S. Rumyantsev A.; Dmitry Rogachev Federal ResearchandClinical Center for Pediatric Hematology, Oncology, and Immunology, Ministry of Health of the Russian Federation; N. I. Pirogov National Research Medical University, Ministry of Health of the Russian Federation, N. Samsonova N.; A. N. Bakulev Research Center of Cardiovascular Surgery, L. Klimovich G.; A. N. Bakulev Research Center of Cardiovascular Surgery, E. Kornienko A.; A. A. Vishnevsky Central Military Clinical Hospital Three, Ministry of Defense of the Russian Federation, Е. Гончарова И.; 3-й центральный военный клинический госпиталь им. А. А. Вишневского Минобороны России, Е. Спиридонова А.; Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России; Московский государственный медико-стоматологический университет им. А. И. Евдокимова Минздрава России, А. Баландина Н.; Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России, А. Полетаев В.; Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России, А. Сепоян М.; Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России, Ф. Атауллаханов И.; Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России; Центр теоретических проблем физико-химической фармакологии РАН, С. Румянцев А.; Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России; Национальный исследовательский медицинский университет им. Н. И. Пирогова Минздрава России, Н. Самсонова Н.; Научный центр сердечно-сосудистой хирургии им. А. Н. Бакулева, Л. Климович Г.; Научный центр сердечно-сосудистой хирургии им. А. Н. Бакулева, Е. Корниенко А.; 3-й центральный военный клинический госпиталь им. А. А. Вишневского Минобороны России, E. Goncharova I.; A. A. Vishnevsky Central Military Clinical Hospital Three, Ministry of Defense of the Russian Federation, E. Spiridonova A.; Dmitry Rogachev Federal ResearchandClinical Center for Pediatric Hematology, Oncology, and Immunology, Ministry of Health of the Russian Federation; A. I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the Russian Federation, A. Balandina N.; Dmitry Rogachev Federal ResearchandClinical Center for Pediatric Hematology, Oncology, and Immunology, Ministry of Health of the Russian Federation, A. Poletaev V.; Dmitry Rogachev Federal ResearchandClinical Center for Pediatric Hematology, Oncology, and Immunology, Ministry of Health of the Russian Federation, A. Sepoyan M.; Dmitry Rogachev Federal ResearchandClinical Center for Pediatric Hematology, Oncology, and Immunology, Ministry of Health of the Russian Federation, F. Ataullakhanov I.; Dmitry Rogachev Federal ResearchandClinical Center for Pediatric Hematology, Oncology, and Immunology, Ministry of Health of the Russian Federation; Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, S. Rumyantsev A.; Dmitry Rogachev Federal ResearchandClinical Center for Pediatric Hematology, Oncology, and Immunology, Ministry of Health of the Russian Federation; N. I. Pirogov National Research Medical University, Ministry of Health of the Russian Federation, N. Samsonova N.; A. N. Bakulev Research Center of Cardiovascular Surgery, L. Klimovich G.; A. N. Bakulev Research Center of Cardiovascular Surgery, E. Kornienko A.; A. A. Vishnevsky Central Military Clinical Hospital Three, Ministry of Defense of the Russian Federation, Е. Гончарова И.; 3-й центральный военный клинический госпиталь им. А. А. Вишневского Минобороны России, Е. Спиридонова А.; Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России; Московский государственный медико-стоматологический университет им. А. И. Евдокимова Минздрава России, А. Баландина Н.; Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России, А. Полетаев В.; Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России, А. Сепоян М.; Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России, Ф. Атауллаханов И.; Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России; Центр теоретических проблем физико-химической фармакологии РАН, С. Румянцев А.; Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России; Национальный исследовательский медицинский университет им. Н. И. Пирогова Минздрава России, Н. Самсонова Н.; Научный центр сердечно-сосудистой хирургии им. А. Н. Бакулева, Л. Климович Г.; Научный центр сердечно-сосудистой хирургии им. А. Н. Бакулева, and Е. Корниенко А.; 3-й центральный военный клинический госпиталь им. А. А. Вишневского Минобороны России

Abstract

Objective: to reveal early changes in the hemostatic system during warfarin therapy in cardiac surgical patients, by comprehensively evaluating their hemostatic status.Subjects and methods. Seventyfive patients receiving cardiac surgical treatment were examined. All the patients took warfarin for 5±1.5 days. Laboratory studies involving the determination of routine coagulogram readings and thrombodynamic indicators (lag time (Tlag) and rate (Vs) of clot growth, and concentrations of individual Factors II, VI, IX, and X) were used to evaluate the patients' hemostatic status.Results. 28% of the patients were found to have an international normalized ratio (INR) of above 3.0. There was a correlation of Tlag with INR (R2=0.66). Both indicators were comparatively highly correlated with Factor II and Factor X concentrations (R2=0.50 and 0.40 for Tlag; R2=0.53 and 0.48 for INR) and were uncorrelated with Factor IX levels (R2=0.20 for Tlag and 0.34 for INR). However, there was a difference in Factor VII concentrations: no correlation for Tlag (R2=0.20) whereas it for INR was rather high (R2=0.42). The index Vs was uncorrelated with INR (R2=0.24) and the concentration of blood coagulation factors (R2<0.1). There was a high correlation between Factor II and Factor X concentrations (R2=0.87); the correlation between the concentrations of all other pairs of coagulation factors was substantially lower (R20.45). The lack of correlation of a thrombodynamic indicator, such as clot growth rate, with the concentration of coagulation factors points to the fact that warfarin acts mainly on the phase of coagulation activation rather than that of clot propagation.Conclusion. The weak correlation between coagulation factors (except that of a pair of Factor II and Factor X) is indicative of the individual response of the patients to warfarin treatment and the need to monitor the hemostatic status by global hemostatic tests rather than by individual proteins. The thrombodynamic indicato, Цель работы. Выявление ранних изменений в системе гемостаза при терапии варфарином у кардиохирургических больных путем комплексной оценки гемостатического статуса пациентов.Материалы и методы. Исследовано 75 пациентов, проходивших кардиохирургическое лечение. Все пациенты получали варфарин (продолжительность лечения больных — 5±1,5 суток). Для оценки гемостатического статуса больных использовали лабораторные методы, включающие определение рутинных показателей коагулограммы, тромбодинамики (время задержки Tlag и скорости роста сгустка (Vs), исследования концентрации II, VII, IX, X факторов).Результаты. Установлено, что у 28%больных показатель МНО находился в области свыше 3.0. Установлена корреляция Tlag с MНО (R2=0,66). Оба показателя имеют сравнительно высокую корреляцию с концентрацией FII и FX (R2=0,50 и 0,40 для Tlag, R2=0,53 и 0,48 для МНО) и не коррелируют с концентрацией FIX (R2=0,20 для Tlag и 0,34 для МНО). Однако наблюдается расхождение в случае концентрации FVII: корреляция для Tlag отсутствует (R2=0,20), тогда как для МНО она достаточно высока (R2=0,42). Параметр Vs не коррелирует с МНО (R2=0,24) и концентрацией факторов свертывания (R2<0,1). Обнаружена высокая корреляция между концентрациями факторов FII и FX (R2=0,87), корреляция между концентрациями всех других пар факторов свертывания существенно ниже (R20,45). Отсутствие корреляции такого показателя тромбодинамики как скорость роста сгустка от концентрации факторов указывает на то, что варфарин действует преимущественно на фазу активации свертывания, но не на фазу распространения сгустка.Заключение. Слабая корреляция факторов свертывания между собой (за исключением пары фактор II — фактор X) указывает на индивидуальный ответ больных на лечение варфарином и необходимость мониторинга состояния гемостаза не по отдельным белкам, а глобальными тестами. Параметр Tlag в тромбодинамике отражает эффект варфарина пропорционально МНО. Варфарин практически не влияет на скорость роста сгустка Vs, поэтому дан

Published
2015

7. Synthesis and structure of 2′-substituted 1-(1,3-dioxan-5-yl)uracils. Positive role of the Eu(fod)3 nmr shift reagent

Author

Samitov Y., Goncharova I., Ramzaeva N., Mishnev A., Bleidelis Y., Samitov Y., Goncharova I., Ramzaeva N., Mishnev A., and Bleidelis Y.

Abstract

The configuration of 1-(2-R-1,3-dioxan-5-yl)uracils and the conformation of the dioxane ring in these compounds were investigated by 1H NMR spectroscopy with the aid of the Eu(fod)3 shift reagent. It is shown that the dioxane ring exists in the preferred chair conformation with an axial orientation of the pyrimidine ring; this is confirmed by the resonance of the 5′-Ha proton in the form of a broad singlet with υ1/2υ8.5 Hz. An analysis of the spectral peculiarities of the synthesized compounds made it possible to establish the orientation of the substituents attached to the second C2 steric center. The three-dimensional structure of 1-(2, 2-dimethyl-1,3-dioxan-5-yl)uracil was determined by an x-ray diffraction study, and the axial orientation of the pyrimidine ring was confirmed. It is shown that significant flattening of the carbon part of the ring (ψ = 46.6 °) is observed in this molecule. An intramolecular (C6...O1, = 3.05 Å) hydrogen bond was observed in the molecule of this compound. © 1982 Plenum Publishing Corporation.

8. Synthesis and structure of 2′-substituted 1-(1,3-dioxan-5-yl)uracils. Positive role of the Eu(fod)3 nmr shift reagent

Author

Samitov Y., Goncharova I., Ramzaeva N., Mishnev A., Bleidelis Y., Samitov Y., Goncharova I., Ramzaeva N., Mishnev A., and Bleidelis Y.

Abstract

The configuration of 1-(2-R-1,3-dioxan-5-yl)uracils and the conformation of the dioxane ring in these compounds were investigated by 1H NMR spectroscopy with the aid of the Eu(fod)3 shift reagent. It is shown that the dioxane ring exists in the preferred chair conformation with an axial orientation of the pyrimidine ring; this is confirmed by the resonance of the 5′-Ha proton in the form of a broad singlet with υ1/2υ8.5 Hz. An analysis of the spectral peculiarities of the synthesized compounds made it possible to establish the orientation of the substituents attached to the second C2 steric center. The three-dimensional structure of 1-(2, 2-dimethyl-1,3-dioxan-5-yl)uracil was determined by an x-ray diffraction study, and the axial orientation of the pyrimidine ring was confirmed. It is shown that significant flattening of the carbon part of the ring (ψ = 46.6 °) is observed in this molecule. An intramolecular (C6...O1, = 3.05 Å) hydrogen bond was observed in the molecule of this compound. © 1982 Plenum Publishing Corporation.

9. The effect of feedstock treatment on the deasphalting process

Author

Goncharova I., Safiulina A., Khusnutdinov I., Alawode E., Skvortsova G., Goncharova I., Safiulina A., Khusnutdinov I., Alawode E., and Skvortsova G.

Abstract

© 2018, © 2018 Taylor & Francis Group, LLC. Transportation and further processing techniques of natural bitumen are of high demand nowadays. In the present article, deasphalting of bitumen with low-molecular oxygen containing solvents was proposed. A method for regulating the process of deasphalting aimed at increasing the yield of low-viscosity deasphalted oil was developed. The influence of the depth of distillation and solvent: feed ratio on the yield of the products of deasphalting was revealed. A study on various technological options for the primary processing of natural bitumen and ultra-high-viscosity oils for pipeline transport was conducted.

Catalog

Books, media, physical & digital resources
See catalog results